Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

FLASH Biomarker Study

12. november 2026 opdateret af: Abramson Cancer Center at Penn Medicine

Biomarker Characterization in Patients Undergoing Ultra-High Dose Rate (ConformalFLASH®) on the C-FLASH-01 Trial

This is a single-center, non-interventional biospecimen collection protocol that accompanies C-FLASH-01 (Protocol IBA-04-UP, IDE G260113), a pilot trial of ultra-high dose rate proton reirradiation (ConformalFLASH) for head and neck cancer. Blood and saliva will be collected from up to 10 participants enrolled on the C-FLASH-01 trial at three time points: 1) within 4 weeks before the start of radiotherapy, 2) within 3 days of the last day of radiotherapy, and 3) within 4 months after completion of radiotherapy.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Detaljeret beskrivelse

The study team hypothesize that biomarkers measurable in blood and saliva, including but not limited to cell-free DNA and cytokines, change over the course of ConformalFLASH reirradiation and are associated with normal tissue response/toxicity. This protocol does not include a study intervention; all radiotherapy is delivered under the separately approved parent protocol (Protocol IBA-04-UP, IDE G260113).

Undersøgelsestype

Observationel

Tilmelding (Anslået)

10

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Participants are recruited exclusively from among individuals enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) in the Department of Radiation Oncology at the University of Pennsylvania. No advertising, flyers, social media, or other external recruitment will be used, and no additional screening of the general population is required.

Beskrivelse

Inclusion Criteria:

  • Enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) and planned to receive ConformalFLASH reirradiation
  • Male or female, aged 18 years or older
  • Provision of signed and dated informed consent for this biospecimen protocol
  • Stated willingness to comply with the specimen collection

Exclusion Criteria:

  • Any condition that, in the judgment of the investigator, makes repeated peripheral venipuncture unsafe or infeasible
  • Inability to provide informed consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: OTHER
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Batched analysis of Biomarker dynamics in blood Including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.
Tidsramme: - Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)

Change in biomarker measures (e.g., cell-free DNA and cytokines) in plasma between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy.

At each time point, 16 mL of peripheral blood will be drawn by a trained phlebotomist or delegated study team member into Streck Cell-Free DNA BCT tubes and EDTA tubes. The maximum cumulative volume drawn under this protocol is 48 mL per participant. Streck tubes stabilize cell-free DNA for the cell-free DNA analyses; EDTA tubes provide plasma and buffy coat for cytokine analyses and potential cellular analyses.

At every collection - blood will be centrifuged; plasma and buffy coat aliquoted and stored at - 80 °C.

- Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)
Batched analysis of Biomarker dynamic in the saliva including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.
Tidsramme: - Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)

Change in biomarker measures (e.g., cell-free DNA and cytokines) in saliva between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy.

At each time point, saliva will be collected into a commercial saliva collection tube in accordance with the manufacturer's instructions, after the 30-minute interval.

At every collection - Saliva will be stored at - 80 °C.

- Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Shervin Tabrizi, MD, University of Pennsylvania

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. november 2029

Studieafslutning (Anslået)

1. november 2029

Datoer for studieregistrering

Først indsendt

30. oktober 2026

Først indsendt, der opfyldte QC-kriterier

12. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • UPCC 16326
  • 26-8473 (Anden identifikator: University of Pennsylvania, Internal Review Broad (IRB))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner